

# Benjamin Maasoumy

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/3951759/benjamin-maasoumy-publications-by-citations.pdf>  
**Version:** 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

72 papers	1,250 citations	19 h-index	33 g-index
94 ext. papers	1,698 ext. citations	5.7 avg, IF	4.69 L-index

#	Paper	IF	Citations
72	Natural history of acute and chronic hepatitis C. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , <b>2012</b> , 26, 401-12	2.5	160
71	Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting. <i>PLoS ONE</i> , <b>2013</b> , 8, e55285	3.7	82
70	Viral and Host Responses After Stopping Long-term Nucleos(t)ide Analogue Therapy in HBeAg-Negative Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , <b>2016</b> , 214, 1492-1497	7	78
69	Hepatitis B core-related antigen (HBcrAg) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D. <i>Clinical Microbiology and Infection</i> , <b>2015</b> , 21, 606.e1-10	9.5	75
68	Drug-Drug Interactions With Novel All Oral Interferon-Free Antiviral Agents in a Large Real-World Cohort. <i>Clinical Infectious Diseases</i> , <b>2016</b> , 62, 561-7	11.6	72
67	Prothrombotic immune thrombocytopenia after COVID-19 vaccination. <i>Blood</i> , <b>2021</b> , 138, 350-353	2.2	69
66	Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimens. <i>Journal of Hepatology</i> , <b>2016</b> , 65, 473-82	13.4	55
65	Clinical utility of HCV core antigen detection and quantification in the diagnosis and management of patients with chronic hepatitis C receiving an all-oral, interferon-free regimen. <i>Antiviral Therapy</i> , <b>2018</b> , 23, 211-217	1.6	42
64	Dominance of hepatitis C virus (HCV) is associated with lower quantitative hepatitis B surface antigen and higher serum interferon-Induced protein 10 levels in HBV/HCV-coinfected patients. <i>Clinical Microbiology and Infection</i> , <b>2015</b> , 21, 710.e1-9	9.5	35
63	HCV core antigen as an alternative to HCV RNA testing in the era of direct-acting antivirals: retrospective screening and diagnostic cohort studies. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2018</b> , 3, 856-864	18.8	32
62	Treatment of Chronic Hepatitis C: Efficacy, Side Effects and Complications. <i>Visceral Medicine</i> , <b>2019</b> , 35, 161-170	2.4	31
61	The clinical significance of drug-drug interactions in the era of direct-acting anti-viral agents against chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2013</b> , 38, 1365-72	6.1	30
60	Detection of low HCV viraemia by repeated HCV RNA testing predicts treatment failure to triple therapy with telaprevir. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 39, 85-92	6.1	26
59	HCV core antigen as an alternate test to HCV RNA for assessment of virologic responses to all-oral, interferon-free treatment in HCV genotype 1 infected patients. <i>Journal of Virological Methods</i> , <b>2017</b> , 245, 14-18	2.6	24
58	Induction of a mature hepatocyte phenotype in adult liver derived progenitor cells by ectopic expression of transcription factors. <i>Stem Cell Research</i> , <b>2011</b> , 6, 251-61	1.6	23
57	Dose-dependent impact of proton pump inhibitors on the clinical course of spontaneous bacterial peritonitis. <i>Liver International</i> , <b>2018</b> , 38, 1602-1613	7.9	21
56	Systemic arterial blood pressure determines the therapeutic window of non-selective beta blockers in decompensated cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 50, 696-706	6.1	21

55	What is new on HBsAg and other diagnostic markers in HBV infection?. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , <b>2017</b> , 31, 281-289	2.5	19
54	Diagnostics in hepatitis C: The end of response-guided therapy?. <i>Journal of Hepatology</i> , <b>2016</b> , 65, S67-S81	3.4	19
53	Applicability of Hepatitis C Virus RNA Viral Load Thresholds for 8-Week Treatments in Patients With Chronic Hepatitis C Virus Genotype 1 Infection. <i>Clinical Infectious Diseases</i> , <b>2016</b> , 62, 1228-1234	11.6	19
52	Eligibility and safety of the first interferon-free therapy against hepatitis C in a real-world setting. <i>Liver International</i> , <b>2015</b> , 35, 1845-52	7.9	19
51	Limited effectiveness and safety profile of protease inhibitor-based triple therapy against chronic hepatitis C in a real-world cohort with a high proportion of advanced liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2014</b> , 26, 836-45	2.2	19
50	Evaluation of the COBAS( ) AmpliPrep/COBAS( ) TaqMan( ) HCV Test, v2.0 and comparison to assays used in routine clinical practice in an international multicenter clinical trial: The ExPECT study. <i>Journal of Clinical Virology</i> , <b>2015</b> , 67, 67-72	14.5	17
49	Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE). <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> ,	6.9	17
48	Multicenter Comparison Study of both Analytical and Clinical Performance across Four Roche Hepatitis C Virus RNA Assays Utilizing Different Platforms. <i>Journal of Clinical Microbiology</i> , <b>2017</b> , 55, 1131-1139	9.7	15
47	Hepatitis B Core-Related Antigen to Indicate High Viral Load: Systematic Review and Meta-Analysis of 10,397 Individual Participants. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 46-60.e8	6.9	15
46	Letter: Telaprevir triple therapy in chronic hepatitis C genotype 1 patients receiving haemodialysis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 39, 1342-4	6.1	14
45	New viral biomarkers for Hepatitis B: Are we able to change practice?. <i>Journal of Viral Hepatitis</i> , <b>2018</b> , 25, 1226-1235	3.4	14
44	Treatment of naïve patients with chronic hepatitis C genotypes 2 and 3 with pegylated interferon alpha and ribavirin in a real world setting: relevance for the new era of DAA. <i>PLoS ONE</i> , <b>2014</b> , 9, e108751	13.7	13
43	Performance of two HCV RNA assays during protease inhibitor-based triple therapy in patients with advanced liver fibrosis and cirrhosis. <i>PLoS ONE</i> , <b>2014</b> , 9, e110857	3.7	13
42	MAIT Cells Are Enriched and Highly Functional in Ascites of Patients With Decompensated Liver Cirrhosis. <i>Hepatology</i> , <b>2020</b> , 72, 1378-1393	11.2	13
41	Frequency of Potential Drug-Drug Interactions in the Changing Field of HCV Therapy. <i>Open Forum Infectious Diseases</i> , <b>2020</b> , 7, ofaa040	1	11
40	Clinical significance of detectable and quantifiable HCV RNA at the end of treatment with ledipasvir/sofosbuvir in GT1 patients. <i>Liver International</i> , <b>2018</b> , 38, 1906-1910	7.9	11
39	Association Between Type 2 Diabetes Mellitus, HbA1c and the Risk for Spontaneous Bacterial Peritonitis in Patients with Decompensated Liver Cirrhosis and Ascites. <i>Clinical and Translational Gastroenterology</i> , <b>2018</b> , 9, 189	4.2	11
38	Commutability and concordance of four hepatitis B virus DNA assays in an international multicenter study. <i>Therapeutic Advances in Gastroenterology</i> , <b>2017</b> , 10, 609-618	4.7	9

37	The impact of proton pump inhibitors on the intestinal microbiota in chronic hepatitis C patients. <i>Scandinavian Journal of Gastroenterology</i> , <b>2019</b> , 54, 1033-1041	2.4	8
36	Optimal treatment with boceprevir for chronic HCV infection. <i>Liver International</i> , <b>2013</b> , 33 Suppl 1, 14-22.	7.9	8
35	Sustained impact of nosocomial-acquired spontaneous bacterial peritonitis in different stages of decompensated liver cirrhosis. <i>PLoS ONE</i> , <b>2019</b> , 14, e0220666	3.7	6
34	Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels.. <i>Journal of Hepatology</i> , <b>2022</b> ,	13.4	6
33	Hepatitis C RNA assay differences in results: Potential implications for shortened therapy and determination of Sustained Virologic Response. <i>Scientific Reports</i> , <b>2016</b> , 6, 35410	4.9	5
32	How to interpret borderline HCV antibody test results: a comparative study investigating four different anti-HCV assays. <i>Viral Immunology</i> , <b>2014</b> , 27, 7-13	1.7	5
31	Letter: a 5-year long-term follow-up study after DAA treatment confirms a reduced HCC risk in a central European cohort of HCV patients with liver cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 51, 194-195	6.1	5
30	Freiburg index of post-TIPS survival (FIPS) a valid prognostic score in patients with cirrhosis but also an advisor against TIPS?. <i>Journal of Hepatology</i> , <b>2021</b> , 75, 487-489	13.4	5
29	Frequency, characteristics and impact of multiple consecutive nosocomial infections in patients with decompensated liver cirrhosis and ascites. <i>United European Gastroenterology Journal</i> , <b>2020</b> , 8, 567-576	5.3	4
28	Only partial improvement in health-related quality of life after treatment of chronic hepatitis C virus infection with direct acting antivirals in a real-world setting-results from the German Hepatitis C-Registry (DHC-R). <i>Journal of Viral Hepatitis</i> , <b>2021</b> , 28, 1206-1218	3.4	4
27	Impact of HBsAg and HBcrAg levels on phenotype and function of HBV-specific T cells in patients with chronic hepatitis B virus infection. <i>Gut</i> , <b>2021</b> ,	19.2	3
26	Pilot Study Using Machine Learning to Identify Immune Profiles for the Prediction of Early Virological Relapse After Stopping Nucleos(t)ide Analogues in HBeAg-Negative CHB. <i>Hepatology Communications</i> , <b>2021</b> , 5, 97-111	6	3
25	Stomach reduction or gastric bypass as risk factor for treatment failure after DAA therapy for hepatitis C?. <i>Journal of Hepatology</i> , <b>2018</b> , 68, 851-853	13.4	3
24	HBV-RNA Co-amplification May Influence HBV DNA Viral Load Determination. <i>Hepatology Communications</i> , <b>2020</b> , 4, 983-997	6	2
23	Incremental value of HBcrAg to classify 1582 HBeAg-negative individuals in chronic infection without liver disease or hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 53, 733-744	6.1	2
22	Prospective assessment of subclinical cardiovascular damage and associated factors in liver transplant recipients. <i>Transplant International</i> , <b>2021</b> , 34, 127-138	3	2
21	Quantification of polyreactive immunoglobulin G facilitates the diagnosis of autoimmune hepatitis. <i>Hepatology</i> , <b>2021</b> ,	11.2	2
20	Reply. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 2681-2682	6.9	2

19	Safety and feasibility of transjugular intrahepatic portosystemic shunt in elderly patients with liver cirrhosis and refractory ascites. <i>PLoS ONE</i> , <b>2020</b> , 15, e0235199	3.7	1
18	Performance of Roche qualitative HEV assay on the cobas 6800 platform for quantitative measurement of HEV RNA. <i>Journal of Clinical Virology</i> , <b>2020</b> , 129, 104525	14.5	1
17	Extrahepatic Manifestations of Hepatitis C Virus Infection <b>2013</b> , 295-309		1
16	Interdependent Impact of Lipoprotein Receptors and Lipid-Lowering Drugs on HCV Infectivity. <i>Cells</i> , <b>2021</b> , 10,	7.9	1
15	IgG, a novel predictor for acute-on-chronic liver failure and survival in patients with decompensated cirrhosis?. <i>Journal of Hepatology</i> , <b>2021</b> , 75, 229-231	13.4	1
14	Utility of the new cobas HCV test for viral load monitoring during direct-acting antiviral therapy. <i>PLoS ONE</i> , <b>2019</b> , 14, e0224751	3.7	1
13	A transient early HBV-DNA increase during PEG-IFN $\alpha$ therapy of hepatitis D indicates loss of infected cells and is associated with HDV-RNA and HBsAg reduction. <i>Journal of Viral Hepatitis</i> , <b>2021</b> , 28, 410-419	3.4	1
12	Antimicrobial resistance in patients with decompensated liver cirrhosis and bacterial infections in a tertiary center in Northern Germany. <i>BMC Gastroenterology</i> , <b>2021</b> , 21, 296	3	1
11	Reliable quantification of plasma HDV RNA is of paramount importance for treatment monitoring: A European multicenter study. <i>Journal of Clinical Virology</i> , <b>2021</b> , 142, 104932	14.5	1
10	Percutaneous Transsplenic Balloon-Assisted Transjugular Intrahepatic Portosystemic Shunt Placement in Patients with Portal Vein Obliteration for Portal Vein Recanalization: Feasibility, Safety and Effectiveness.. <i>CardioVascular and Interventional Radiology</i> , <b>2022</b> , 45, 696	2.7	0
9	Significant compartment-specific impact of different RNA extraction methods and PCR assays on the sensitivity of hepatitis E virus detection. <i>Liver International</i> , <b>2021</b> , 41, 1815-1823	7.9	0
8	Reaching the Unreachable: Strategies for HCV Eradication in Patients With Refractory Opioid Addiction-A Real-world Experience. <i>Open Forum Infectious Diseases</i> , <b>2021</b> , 8, ofab325	1	0
7	Plasma and ascites pharmacokinetic of meropenem in patients with decompensated cirrhosis and spontaneous bacterial peritonitis. <i>Journal of Hepatology</i> , <b>2021</b> ,	13.4	0
6	Impact of the COVID-19 pandemic on patients with liver cirrhosis-the experience of a tertiary center in Germany. <i>Zeitschrift Fur Gastroenterologie</i> , <b>2021</b> , 59, 954-960	1.6	0
5	Commentary: detection of low level viraemia in telaprevir-based triple therapy for hepatitis C virus - authorsTreply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 39, 544-5	6.1	
4	Reply to: "HCV RNA kinetics on-treatment do not predict sustained virologic response in HCV genotype 3 patients receiving sofosbuvir and ribavirin". <i>Journal of Hepatology</i> , <b>2016</b> , 65, 1059-1060	13.4	
3	Reply. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> ,	6.9	
2	Nosocomial infections in female compared with male patients with decompensated liver cirrhosis.. <i>Scientific Reports</i> , <b>2022</b> , 12, 3285	4.9	

- 1 FIB-4 and APRI as Predictive Factors for Short- and Long-Term Survival in Patients with Transjugular Intrahepatic Portosystemic Stent Shunts. *Biomedicines*, **2022**, 10, 1018 4.8